

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese)
BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Financial Statements

**With Independent Auditors' Review Report
For the Six Months Ended June 30, 2025 and 2024**

Address: 5F.-6, No.23, Sec.1. Chang-An E. Rd., Taipei City 104, Taiwan (R.O.C.)
Telephone: +886-2-2571-0269

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~31
(7) Related-party transactions	31
(8) Assets Pledged as security	32
(9) Commitments and contingencies	32
(10) Losses Due to Major Disasters	32
(11) Subsequent Events	32
(12) Other	33
(13) Other disclosures	
(a) Information on significant transactions	34~35
(b) Information on investees	36
(c) Information on investment in mainland China	36
(14) Segment information	36~37



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電 話 Tel + 886 2 8101 6666
傳 真 Fax + 886 2 8101 6667
網 址 Web kpmg.com/tw

3

Independent Auditors' Review Report

To the Board of Directors of Bioteque Corporation:

Introduction

We have reviewed the accompanying consolidated balance sheets of Bioteque Corporation (the "Company") and its subsidiaries (together referred to as the "Group") as of June 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three months and six months ended June 30, 2025 and 2024, as well as the changes in equity and cash flows for the six months ended June 30, 2025 and 2024, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Bioteque Corporation and its subsidiaries as of June 30, 2025 and 2024, and of its consolidated financial performance for the three months and six months ended June 30, 2025 and 2024, as well as its consolidated cash flows for the six months ended June 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Cheng, Po-Jen and Huang, Ming-Hung.

KPMG

Taipei, Taiwan (Republic of China)
August 7, 2025

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

June 30, 2025, December 31, 2024 and June 30, 2024

(Expressed in Thousands of New Taiwan Dollars)

	Assets							Liabilities and Equity						
	June 30, 2025		December 31, 2024		June 30, 2024			June 30, 2025		December 31, 2024		June 30, 2024		
	Amount	%	Amount	%	Amount	%		Amount	%	Amount	%	Amount	%	
Assets														
Current assets :														
1100 Cash and cash equivalents (note 6(a))	\$ 1,244,353	26	1,236,955	27	1,537,662	32	2130	Current contract liabilities (note 6(n))	\$ 57,560	1	57,542	1	40,458	1
1110 Current financial assets at fair value through profit or loss (note 6(b))	121,186	3	120,280	3	119,394	3	2150	Notes payable	102	-	289	-	163	-
1136 Current financial assets at amortized cost (note 6(c))	441,044	9	239,213	5	102,817	2	2170	Accounts payable	90,144	2	114,547	3	135,034	3
1150 Notes receivable, net (notes 6(d) and (n))	74,484	1	75,470	2	66,943	1	2209	Other payables (notes 6(j) and (o))	146,189	3	140,334	3	149,787	3
1170 Accounts receivable, net (notes 6(d) and (n))	183,733	4	192,657	4	203,901	4	2216	Payable on machinery and equipment	3,906	-	7,995	-	85,936	2
130X Inventories (note 6(e))	281,456	6	320,701	7	291,059	6	2230	Dividends payable (notes 6(l) and 7)	346,492	7	-	-	311,843	7
1476 Other current financial assets (note 8)	601	-	601	-	601	-	2280	Current tax liabilities	66,263	2	78,648	2	65,126	1
1479 Other current assets	48,638	1	29,891	-	38,249	1	2322	Current lease liabilities (note 6(i))	14,432	-	8,952	-	11,526	-
Total current assets	<u>2,395,495</u>	<u>50</u>	<u>2,215,768</u>	<u>48</u>	<u>2,360,626</u>	<u>49</u>	2399	Long-term borrowings, current portion (note 6(h))	150,913	3	149,800	3	158,808	3
Non-current assets:								Other current liabilities	11,193	-	7,241	-	11,262	-
1600 Property, plant and equipment (notes 6(f), 8 and 9)	1,964,889	42	2,030,526	44	2,069,745	43		Total current liabilities	<u>887,194</u>	<u>18</u>	<u>565,348</u>	<u>12</u>	<u>969,943</u>	<u>20</u>
1755 Right-of-use assets (note 6(g))	348,144	7	340,467	7	346,859	7	2541	Non-Current liabilities:						
1840 Deferred tax asset	3,691	-	3,691	-	6,520	-	2570	Long-term borrowings (note 6(h))	220,417	5	296,429	7	371,329	8
1915 Prepayments for business facilities (note 9)	25,240	1	45,325	1	45,296	1	2580	Deferred tax liabilities	49,035	1	49,035	1	45,445	1
1980 Other non-current financial assets	4,117	-	3,655	-	3,623	-	2640	Non-current lease liabilities (note 6(i))	292,938	7	285,452	6	289,231	6
1995 Other non-current assets	6,257	-	5,979	-	6,953	-		Net defined benefit liability, non-current	8,177	-	8,177	-	8,285	-
Total non-current assets	<u>2,352,338</u>	<u>50</u>	<u>2,429,643</u>	<u>52</u>	<u>2,478,996</u>	<u>51</u>		Total non-current liabilities	<u>570,567</u>	<u>13</u>	<u>639,093</u>	<u>14</u>	<u>714,290</u>	<u>15</u>
Total assets	<u><u>\$ 4,747,833</u></u>	<u><u>100</u></u>	<u><u>4,645,411</u></u>	<u><u>100</u></u>	<u><u>4,839,622</u></u>	<u><u>100</u></u>		Total liabilities	<u>1,457,761</u>	<u>31</u>	<u>1,204,441</u>	<u>26</u>	<u>1,684,233</u>	<u>35</u>
Equity attributable to owners of parent (note 6(l)):														
3100 Ordinary shares								Ordinary shares	692,983	14	692,983	15	692,983	14
3200 Capital surplus								Capital surplus	317,029	7	317,032	7	316,950	7
3310 Retained earnings:								Retained earnings:						
3350 Legal reserve								Legal reserve	609,767	13	556,910	12	556,910	11
3350 Unappropriated retained earnings								Unappropriated retained earnings	1,676,979	35	1,829,327	39	1,550,966	32
									2,286,746	48	2,386,237	51	2,107,876	43
Other equity:														
3410 Exchange differences on translation of foreign financial statements								Other equity:						
								Exchange differences on translation of foreign financial statements	(6,686)	-	44,718	1	37,580	1
									3,290,072	69	3,440,970	74	3,155,389	65
								Total equity	<u><u>\$ 4,747,833</u></u>	<u><u>100</u></u>	<u><u>4,645,411</u></u>	<u><u>100</u></u>	<u><u>4,839,622</u></u>	<u><u>100</u></u>
								Total liabilities and equity						

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Comprehensive Income****For the three months and six months ended June 30, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)**

	For the three months ended June 30				For the six months ended June 30			
	2025		2024		2025		2024	
	Amount	%	Amount	%	Amount	%	Amount	%
4000 Operating revenue (note 6(n))	\$ 530,457	100	518,754	100	\$ 1,049,020	100	1,015,015	100
5000 Operating costs (notes 6(e), (f), (g), (j) and 12)	306,507	58	300,970	58	600,372	57	592,022	58
Gross profit from operations	<u>223,950</u>	<u>42</u>	<u>217,784</u>	<u>42</u>	<u>448,648</u>	<u>43</u>	<u>422,993</u>	<u>42</u>
6000 Operating expenses (notes 6(f), (g), (i), (j), (o), 7 and 12):								
6100 Selling expenses	18,173	3	20,681	4	40,074	4	40,540	4
6200 Administrative expenses	24,748	5	25,457	5	50,185	5	50,120	5
6300 Research and development expenses	18,620	3	20,084	4	36,862	3	40,275	4
Total operating expenses	<u>61,541</u>	<u>11</u>	<u>66,222</u>	<u>13</u>	<u>127,121</u>	<u>12</u>	<u>130,935</u>	<u>13</u>
6900 Net operating income	<u>162,409</u>	<u>31</u>	<u>151,562</u>	<u>29</u>	<u>321,527</u>	<u>31</u>	<u>292,058</u>	<u>29</u>
7000 Non-operating income and expenses (notes 6(i) and (p)):								
7100 Interest income	4,282	-	3,292	1	8,370	-	6,951	-
7010 Other income	1,074	-	1,447	-	2,971	-	2,430	-
7020 Other gains and losses	(31,585)	(6)	3,720	1	(24,024)	(2)	20,535	2
7050 Finance costs	(1,929)	-	(2,488)	(1)	(3,885)	-	(5,014)	-
Total non-operating income and expenses	<u>(28,158)</u>	<u>(6)</u>	<u>5,971</u>	<u>1</u>	<u>(16,568)</u>	<u>(2)</u>	<u>24,902</u>	<u>2</u>
7900 Profit before tax	<u>134,251</u>	<u>25</u>	<u>157,533</u>	<u>30</u>	<u>304,959</u>	<u>29</u>	<u>316,960</u>	<u>31</u>
7951 Less: Tax expenses (note 6(k))	<u>21,783</u>	<u>4</u>	<u>33,011</u>	<u>6</u>	<u>57,958</u>	<u>5</u>	<u>66,752</u>	<u>6</u>
Profit	<u>112,468</u>	<u>21</u>	<u>124,522</u>	<u>24</u>	<u>247,001</u>	<u>24</u>	<u>250,208</u>	<u>25</u>
8300 Other comprehensive income (loss) (note 6(l)):								
8360 Components of other comprehensive income (loss) that will be reclassified to profit or loss:								
8361 Exchange differences on translation	(59,304)	(11)	5,250	1	(51,404)	(5)	26,897	2
8399 Income tax related to components of other comprehensive income that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
Total components of other comprehensive income (loss) that will be reclassified to profit or loss	<u>(59,304)</u>	<u>(11)</u>	<u>5,250</u>	<u>1</u>	<u>(51,404)</u>	<u>(5)</u>	<u>26,897</u>	<u>2</u>
8300 Other comprehensive income (loss), net	<u>(59,304)</u>	<u>(11)</u>	<u>5,250</u>	<u>1</u>	<u>(51,404)</u>	<u>(5)</u>	<u>26,897</u>	<u>2</u>
Comprehensive income	<u>\$ 53,164</u>	<u>10</u>	<u>129,772</u>	<u>25</u>	<u>195,597</u>	<u>19</u>	<u>277,105</u>	<u>27</u>
9750 Basic earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 1.62</u>		<u>1.80</u>		<u>3.56</u>		<u>3.61</u>	
9850 Diluted earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 1.62</u>		<u>1.79</u>		<u>3.55</u>		<u>3.60</u>	

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Changes in Equity****For the six months ended June 30, 2025 and 2024**

(Expressed in Thousands of New Taiwan Dollars)

Balance at January 1, 2024

Net income for the six months ended June 30, 2024

Other comprehensive income for the six months ended June 30, 2024

Total comprehensive income for the six months ended June 30, 2024

Appropriation and distribution of retained earnings:

Legal reserve

Special reserve

Cash dividends

Balance at June 30, 2024**Balance at January 1, 2025**

Net income for the six months ended June 30, 2025

Other comprehensive income for the six months ended June 30, 2025

Total comprehensive income for the six months ended June 30, 2025

Appropriation and distribution of retained earnings:

Legal reserve

Cash dividends

Change in capital surplus

Balance at June 30, 2025

	Attributable to owners of parent						Other equity	Exchange differences on translation of foreign financial statements	Total equity
				Retained earnings					
	Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings				
Balance at January 1, 2024	\$ 692,983	316,950	511,268	1,102	1,657,141		10,683		3,190,127
Net income for the six months ended June 30, 2024	-	-	-	-	250,208		-		250,208
Other comprehensive income for the six months ended June 30, 2024	-	-	-	-	-		26,897		26,897
Total comprehensive income for the six months ended June 30, 2024	-	-	-	-	250,208		26,897		277,105
Appropriation and distribution of retained earnings:									
Legal reserve	-	-	45,642	-	(45,642)		-		-
Special reserve	-	-	-	(1,102)	1,102		-		-
Cash dividends	-	-	-	-	(311,843)		-		(311,843)
Balance at June 30, 2024	\$ 692,983	316,950	556,910	-	1,550,966	37,580	3,155,389		
Balance at January 1, 2025	\$ 692,983	317,032	556,910	-	1,829,327	44,718	3,440,970		
Net income for the six months ended June 30, 2025	-	-	-	-	247,001		-		247,001
Other comprehensive income for the six months ended June 30, 2025	-	-	-	-	-		(51,404)		(51,404)
Total comprehensive income for the six months ended June 30, 2025	-	-	-	-	247,001		(51,404)		195,597
Appropriation and distribution of retained earnings:									
Legal reserve	-	-	52,857	-	(52,857)		-		-
Cash dividends	-	-	-	-	(346,492)		-		(346,492)
Change in capital surplus	-	(3)	-	-	-		-		(3)
Balance at June 30, 2025	\$ 692,983	317,029	609,767	-	1,676,979	(6,686)	3,290,072		

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Cash Flows****For the six months ended June 30, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars)**

	For the six months ended June 30	
	2025	2024
Cash flows generated from (used in) operating activities:		
Profit before tax	\$ 304,959	316,960
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expenses	83,077	77,078
Amortization expenses	2,125	1,784
Net gains on financial assets at fair value through profit or loss	(906)	(803)
Interest expenses	3,885	5,014
Net (loss) gain on financial assets at amortized cost	2,905	(5,149)
Interest income	(8,370)	(6,951)
Total adjustments to reconcile profit	<u>82,716</u>	<u>70,973</u>
Changes in operating assets:		
Notes receivable	986	536
Accounts receivable	8,924	(12,223)
Inventories	39,245	3,582
Other current assets	(19,074)	(5,328)
Total changes in operating assets	<u>30,081</u>	<u>(13,433)</u>
Changes in operating liabilities:		
Current contract liabilities	18	2,376
Notes payable	(187)	(48)
Accounts payable	(24,403)	(1,767)
Other payables	5,903	13,855
Other current liabilities	3,953	6,138
Net defined benefit liability	-	1
Total changes in operating liabilities	<u>(14,716)</u>	<u>20,555</u>
Total changes in operating assets and liabilities	<u>15,365</u>	<u>7,122</u>
Total adjustments	<u>98,081</u>	<u>78,095</u>
Cash inflow generated from operations	403,040	395,055
Interest received	7,730	6,930
Income taxes paid	(70,343)	(63,441)
Net cash flows generated from operating activities	<u>340,427</u>	<u>338,544</u>
Cash flows generated from (used in) investing activities:		
Acquisition of financial assets at amortized cost	(793,949)	(196,487)
Proceeds from disposal of financial assets at amortized cost	589,213	191,610
Acquisition of property, plant and equipment	(16,727)	(81,812)
Decrease (increase) in other financial assets	(462)	116
Increase in other non-current assets	(2,403)	(3,746)
Decrease (increase) in prepayments for business facilities	(5,069)	26,275
Decrease in payables on machinery and equipment	(4,089)	(17,994)
Net cash used in investing activities	<u>(233,486)</u>	<u>(82,038)</u>
Cash flows generated from (used in) financing activities:		
Repayments of long-term borrowings	(74,899)	(64,485)
Payment of lease liabilities	(6,928)	(6,419)
Dividend paid	(3)	-
Interest paid	(3,933)	(5,105)
Net cash used in financing activities	<u>(85,763)</u>	<u>(76,009)</u>
Effect on exchange rate changes on cash and cash equivalents		
Net increase in cash and cash equivalents	(13,780)	3,350
Cash and cash equivalents at beginning of period	7,398	183,847
Cash and cash equivalents at end of period	<u>\$ 1,244,353</u>	<u>1,353,815</u>
	<u>\$ 1,244,353</u>	<u>1,537,662</u>

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

June 30, 2025 and 2024

**(Expressed in Thousands of New Taiwan Dollars Except for Earnings Per Share
Information and Unless Otherwise Specified)**

(1) Company history

Bioteque Corporation (“the Company”) was incorporation in November, 1991 in accordance with the Company Act and the other related laws and regulations.

The Company's stock was listed on Taipei Exchange on March 4, 2002.

The business operation of the Company and its subsidiaries (together referred to as “the Group”) are as follows:

- (a) Manufacturing, trading and selling of the medical consumable.
- (b) Reinvestment and monopoly investment in securities business.

(2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements were authorized for issuance by the board of directors on August 7, 2025

(3) New standards, amendments and interpretations adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”
- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2026, would not have a significant impact on its consolidated financial statements:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> ● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. ● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. ● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”

(4) Summary of material accounting policies:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by the Financial Supervisory Commission (hereinafter referred to as FSC). The consolidated financial statements do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (altogether referred to “IFRS Accounting Standards” endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2024. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2024.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

Name of investor	Name of subsidiary	Principal activity	Shareholding			Note
			June 30, 2025	December 31, 2024	June 30, 2024	
The Company	BIOTEQUE MEDICAL PHIL. INC.	Manufacturing and Trading of Medical equipment	100.00 %	100.00 %	100.00 %	
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Trading of Medical equipment	100.00 %	100.00 %	100.00 %	

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(c) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting”.

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management’s best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2024.

(6) Explanation of significant accounts:

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2024. Please refer to Note 6 of the 2024 annual consolidated financial statements.

(a) Cash and cash equivalents

	June 30, 2025	December 31, 2024	June 30, 2024
Cash on hand	\$ 914	670	811
Cash in bank	<u>1,243,439</u>	<u>1,236,285</u>	<u>1,536,851</u>
Cash and cash equivalents in the consolidated statement of cash flows	<u><u>\$ 1,244,353</u></u>	<u><u>1,236,955</u></u>	<u><u>1,537,662</u></u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Current financial assets at fair value through profit or loss

	June 30, 2025	December 31, 2024	June 30, 2024
Mandatorily measured at fair value through profit or loss:			
Non-derivative financial assets			
Money market funds and bond funds	\$ <u>121,186</u>	<u>120,280</u>	<u>119,394</u>
(i) For credit risk and market risk, please refer to note 6(q).			
(ii) The financial assets of the Group were not collateralized.			
(c) Current financial assets measured at amortized cost			
Time deposits	<u>\$ 441,044</u>	<u>239,213</u>	<u>102,817</u>

The Group has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

(i) For the six months ended June 30, 2025 and 2024, the Group held domestic time deposits, with the weighted-average interest rates of 1.53%~4.50% and 1.29%~5.45%, respectively, which mature in July to November of 2025 and August to September of 2024, respectively.

(ii) For credit risk, please refer to note 6(q).

(iii) The financial assets of the Group were not collateralized.

(d) Notes and accounts receivables

	June 30, 2025	December 31, 2024	June 30, 2024
Notes receivable	\$ <u>74,484</u>	<u>75,470</u>	<u>66,943</u>
Accounts receivables	<u>183,733</u>	<u>192,657</u>	<u>203,901</u>
	<u>\$ 258,217</u>	<u>268,127</u>	<u>270,844</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information. The loss allowances were determined as follows:

	June 30, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance
Current	\$ 251,438	-	-
1 to 30 days past due	6,779	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-bottom: 5px;"/>	100%	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-top: 5px;"/>
	<u>\$ 258,217</u>		<u>-</u>

	December 31, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance
Current	\$ 265,484	-	-
1 to 30 days past due	8	-	-
31 to 60 days past due	2,635	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-bottom: 5px;"/>	100%	<hr style="border-top: 1px solid black; border-bottom: none; border-left: none; border-right: none; margin-top: 5px;"/>
	<u>\$ 268,127</u>		<u>-</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

		June 30, 2024		
	Gross carrying amount	Weighted-average loss rate	Loss allowance	
Current	\$ 267,192	-	-	-
1 to 30 days past due	3,652	-	-	-
31 to 60 days past due	-	-	-	-
61 to 90 days past due	-	-	-	-
91 to 120 days past due	-	-	-	-
121 to 150 days past due	-	-	-	-
151 to 180 days past due	-	4.27%	-	-
More than 181 days past due	-	67%	-	-
	\$ 270,844			-

The allowance for impairment remained unchanged for the six months ended June 30, 2024 and June 30, 2025, and the balance of the allowance for impairment as of June 30, 2025 and June 30, 2024.

The notes and accounts receivables of the Group were not collateralized.

For further credit risk information, please refer to note 6(q).

(e) Inventories

	June 30, 2025	December 31, 2024	June 30, 2024
Raw materials	\$ 133,950	166,523	145,614
Work in progress	64,390	66,133	60,029
Finished goods	40,528	56,369	58,463
Merchandise	18,822	11,621	12,161
Inventories in transit	23,766	20,055	14,792
	\$ 281,456	320,701	291,059

Except for cost of goods sold and inventories recognized as operating cost, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Gains on physical inventory	\$ (440)	(390)	(553)	(600)
Unallocated production overheads	21,463	23,234	43,604	41,708
Losses on valuation of inventories	315	1,800	4,105	1,800
	\$ 21,338	24,644	47,156	42,908

The inventories of the Group were not collateralized.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(f) Property, plant and equipment

The cost and accumulated depreciation of the property, plant and equipment of the Group for the six months ended June 30, 2025 and 2024 were as follows:

	Land	Building and structures	Machinery and equipment	Transportation equipment	Office equipment	Other equipment	Construction in progress	Total
Cost:								
Balance at January 1, 2025	\$ 91,834	2,041,818	1,025,860	13,997	39,721	263,867	-	3,477,097
Additions	-	-	7,321	-	1,176	6,853	1,377	16,727
Disposals	-	-	(5,660)	-	-	(576)	-	(6,236)
Reclassification (Note 1)	-	-	21,486	-	2,839	3,172	(1,377)	26,120
Effect on changes in foreign exchange rates	-	(35,209)	(14,644)	(252)	(234)	(7,642)	-	(57,981)
Balance at June 30, 2025	\$ 91,834	2,006,609	1,034,363	13,745	43,502	265,674	-	3,455,727
Balance at January 1, 2024	\$ 91,834	1,819,008	994,554	11,385	22,295	241,428	57,981	3,238,485
Additions	-	64,740	4,730	2,357	5,495	4,054	436	81,812
Disposals	-	-	-	-	-	(1,354)	-	(1,354)
Reclassification (Note 1)	-	131,865	273	-	10,915	4,862	(58,264)	89,651
Effect on changes in foreign exchange rates	-	20,601	8,575	109	54	4,408	-	33,747
Balance at June 30, 2024	\$ 91,834	2,036,214	1,008,132	13,851	38,759	253,398	153	3,442,341
Accumulated depreciation and impairment loss:								
Balance at January 1, 2025	\$ -	376,048	799,947	10,177	21,947	238,452	-	1,446,571
Depreciation	-	27,616	34,129	554	2,694	10,238	-	75,231
Disposals	-	-	(5,660)	-	-	(576)	-	(6,236)
Effect on changes in foreign exchange rates	-	(6,659)	(10,490)	(179)	(193)	(7,207)	-	(24,728)
Balance at June 30, 2025	\$ -	397,005	817,926	10,552	24,448	240,907	-	1,490,838
Balance at January 1, 2024	\$ -	321,739	726,148	8,925	20,934	213,859	-	1,291,605
Depreciation	-	23,477	33,902	484	1,058	10,864	-	69,785
Disposals	-	-	-	-	-	(1,354)	-	(1,354)
Effect on changes in foreign exchange rates	-	3,427	5,170	93	52	3,818	-	12,560
Balance at June 30, 2024	\$ -	348,643	765,220	9,502	22,044	227,187	-	1,372,596
Carrying amounts:								
Balance at January 1, 2025	\$ 91,834	1,665,770	225,913	3,820	17,774	25,415	-	2,030,526
Balance at June 30, 2025	\$ 91,834	1,609,604	216,437	3,193	19,054	24,767	-	1,964,889
Balance at January 1, 2024	\$ 91,834	1,497,269	268,406	2,460	1,361	27,569	57,981	1,946,880
Balance at June 30, 2024	\$ 91,834	1,687,571	242,912	4,349	16,715	26,211	153	2,069,745

(Note 1) Prepayments for business facilities were reclassified as property, plant and equipment.

As of June 30, 2025, December 31 and June 30, 2024, the property, plant and equipment of the Group had been pledged as collateral for borrowings; please refer to note 8.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(g) Right-of-use assets

The Group leases land and buildings. Information about leases for which the Group has been a lessee is presented below:

	Land	Buildings and structures	Total
Cost:			
Balance at January 1, 2025	\$ 380,494	31,837	412,331
Additions	-	19,894	19,894
Disposals	-	(1,553)	(1,553)
Effect on changes in foreign exchange rates	<u>(5,417)</u>	<u>(114)</u>	<u>(5,531)</u>
Balance at June 30, 2025	<u><u>\$ 375,077</u></u>	<u><u>50,064</u></u>	<u><u>425,141</u></u>
Balance at January 1, 2024	\$ 370,150	31,794	401,944
Additions	6,341	-	6,341
Effect on changes in foreign exchange rates	<u>2,839</u>	<u>2</u>	<u>2,841</u>
Balance at June 30, 2024	<u><u>\$ 379,330</u></u>	<u><u>31,796</u></u>	<u><u>411,126</u></u>
Accumulated depreciation:			
Balance at January 1, 2025	\$ 41,402	30,462	71,864
Depreciation	4,661	3,185	7,846
Disposals	-	(1,553)	(1,553)
Effect on changes in foreign exchange rates	<u>(1,021)</u>	<u>(139)</u>	<u>(1,160)</u>
Balance at June 30, 2025	<u><u>\$ 45,042</u></u>	<u><u>31,955</u></u>	<u><u>76,997</u></u>
Balance at January 1, 2024	\$ 31,521	25,242	56,763
Depreciation	4,662	2,631	7,293
Effect on changes in foreign exchange rates	<u>211</u>	<u>-</u>	<u>211</u>
Balance at June 30, 2024	<u><u>\$ 36,394</u></u>	<u><u>27,873</u></u>	<u><u>64,267</u></u>
Carrying amount:			
Balance at January 1, 2025	\$ 339,092	1,375	340,467
Balance at June 30, 2025	<u><u>\$ 330,035</u></u>	<u><u>18,109</u></u>	<u><u>348,144</u></u>
Balance at January 1, 2024	\$ 338,629	6,552	345,181
Balance at June 30, 2024	<u><u>\$ 342,936</u></u>	<u><u>3,923</u></u>	<u><u>346,859</u></u>

(h) Short-term and long-term borrowings

(i) Short-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	\$ -	-	-
Unused credit lines	<u><u>\$ 760,267</u></u>	<u><u>769,057</u></u>	<u><u>753,343</u></u>
Range of interest rate	-	-	-

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Long-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	\$ 371,330	446,229	530,137
Less: Current portion	<u>150,913</u>	<u>149,800</u>	<u>158,808</u>
Unsecured long-term borrowings	<u>\$ 220,417</u>	<u>296,429</u>	<u>371,329</u>
Unused credit lines	<u>\$ 150,000</u>	<u>150,000</u>	<u>-</u>
Range of interest rate	<u>1.38%~1.45%</u>	<u>1.38%~1.48%</u>	<u>1.375%~6.1%</u>

Parts of the Group's long-term borrowings (included current portion) will be settled in foreign currency. The details of foreign long-term borrowings were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
USD (thousand dollars)	<u>\$ -</u>	<u>-</u>	<u>278</u>
Convert to NTD	<u>\$ -</u>	<u>-</u>	<u>9,008</u>

As of June 30, 2025, the details of the future repayment periods and amounts of the Company's long-term borrowings were as follows:

Period	Amount
2025.07.01~2026.06.30	\$ 150,913
2026.07.01~2027.06.30	134,250
2027.07.01~2028.06.30	86,167
	<u>\$ 371,330</u>

(iii) For the collateral for borrowing, please refer to note 8.

(i) Lease liabilities

	June 30, 2025	December 31, 2024	June 30, 2024
Current	<u>\$ 14,432</u>	<u>8,952</u>	<u>11,526</u>
Non-current	<u>\$ 292,938</u>	<u>285,452</u>	<u>289,231</u>

For the maturity analysis, please refer to note 6(q).

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The amounts recognized in profit or loss were as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Interest on lease liabilities	\$ 584	459	1,024	923
Expenses relating to leases of low-value assets	\$ 15	15	37	30

The amounts recognized in the statement of cash flows by the Group were as follows:

	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Total cash outflow for leases	\$ 7,989	7,372

For the six months ended June 30, 2025 and June 30, 2024, the Group leases land, buildings and structures for its office space, warehouse and parking lot. The leases run for a period of 2 to 20 years. Some leases include an option to renew the lease for an additional period of 2 to 20 years after the end of the contract term.

Some leases of equipment contain extension options exercisable. These leases are negotiated and monitored by local management, and accordingly, contain a wide range of different terms and conditions. The extension options held are exercisable only by the Group and not by the lessors. In which leasee is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(j) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2024 and 2023.

The expenses recognized in profit or loss for the Group were as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Operating costs	\$ 76	76	152	153
Operating expenses	197	193	395	385

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Defined contribution plans

The pension costs incurred from the contributions to the Bureau of the Labor Insurance were as follow:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Operating costs	\$ 1,445	1,468	2,924	2,892
Operating expenses	801	763	1,600	1,544
	\$ 2,246	2,231	4,524	4,436

(iii) The Group's subsidiaries incorporated in the Philippine have a defined contribution plan, wherein a monthly contribution to an independent fund, administered by the government in accordance with the pension regulations in the Republic of the Philippines, are based on certain percentage of employees' monthly salaries and wages. The Group recognized the pension costs were as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Operating costs	\$ 59	42	115	79
Operating expenses	24	25	57	45
	\$ 83	67	172	124

(k) Income taxes

The amounts of income tax were as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Current tax expenses	\$ 21,533	33,811	57,708	67,552
Adjustment for prior periods	250	(800)	250	(800)
Income tax expenses	\$ 21,783	33,011	57,958	66,752

The Company's income tax returns for all years through 2023 were assessed by the tax authorities.

(l) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to June 30, 2025 and 2024. For the related information, please refer to note 6(l) of the consolidated financial statements for the year ended December 31, 2024.

(i) Capital surplus

Balances of capital surplus at the reporting date were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Share capital	\$ 315,168	315,168	315,168
Donation from shareholders	1,861	1,864	1,782
	\$ 317,029	317,032	316,950

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

(ii) **Retained earnings**

The Company's Articles of Incorporation stipulate that 10% of the annual income or earnings, after deducting any accumulated deficit, shall be set aside as a legal reserve. When the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. If there are surplus profits remaining, at least 20% shall be allocated for distribution of shareholder dividends. The Board of Directors drafts a dividend distribution proposal and submits it to the shareholders meeting for resolution, in which cash dividends should make up at least 20% or more.

The Company should distribute dividends, bonuses, and capital reserves with cash. Distribution of dividends shall be undertaken by a resolution adopted by a majority vote at a Board meeting attended by at least two-thirds of the total number of directors, and a report of such distribution shall be submitted to the shareholders' meeting.

Because the industry the Company is involved in is undergoing a steady period of growth, the conditions, amount, and type of dividends mentioned in the preceding articles can be adjusted in response to the shifting market conditions and industry changes. In the mean time, the Company should consider the sustainable development and capital needs.

1) **Legal reserve**

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) **Special reserve**

In accordance with Ruling No. 1010012865 issued by the FSC on April 6, 2012, a portion of current-period earnings and undistributed prior-period earnings shall be reclassified as special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, a portion of undistributed prior-period earnings shall be reclassified as special earnings reserve (which does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. The amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

3) Earnings distribution

On March 6, 2025 and March 6, 2024, the board of directors' meeting resolved to distribute the 2024 and 2023 earnings. These earnings were appropriated as follows:

	2024		2023	
	Amount per share (NTD)	Amount	Amount per share (NTD)	Amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 5.00	<u>346,492</u>	4.50	<u>311,843</u>

(iii) Other equity

	Exchange differences on translation of foreign financial statements
Balance at January 1, 2025	\$ 44,718
Exchange differences on foreign operations	<u>(51,404)</u>
Balance at June 30, 2025	<u>(6,686)</u>
	Exchange differences on translation of foreign financial statements
Balance at January 1, 2024	\$ 10,683
Exchange differences on foreign operations	<u>26,897</u>
Balance at June 30, 2024	<u>37,580</u>

(m) Earnings per share

The Company's earnings per share were calculated as follows:

(i) Basic earnings per share

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Profit attributable to ordinary shareholders of the Company	\$ <u>112,468</u>	<u>124,522</u>	<u>247,001</u>	<u>250,208</u>
Weighted-average number of ordinary shares (in thousand shares)	<u>69,298</u>	<u>69,298</u>	<u>69,298</u>	<u>69,298</u>
Basic earnings per share (express in New Taiwan Dollars)	<u>1.62</u>	<u>1.80</u>	<u>3.56</u>	<u>3.61</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Diluted earnings per share

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Profit attributable to ordinary shareholders of the Company	\$ 112,468	124,522	247,001	250,208
Weighted-average number of ordinary shares (basic) (in thousand shares)	69,298	69,298	69,298	69,298
Effect on employee remuneration (in thousand shares)	136	126	233	218
Weighted-average number of ordinary shares (diluted) (in thousand shares)	69,434	69,424	69,531	69,516
Diluted earnings per share (express in New Taiwan Dollars)	\$ 1.62	1.79	3.55	3.60

(n) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Primary geographical markets:				
Asia	\$ 234,566	229,401	493,034	450,923
South Americas	30,522	45,671	61,309	87,498
North Americas	105,224	93,426	180,512	157,742
Others	160,145	150,256	314,165	318,852
Total	\$ 530,457	518,754	1,049,020	1,015,015
Major products service lines:				
Manufacturing, trading and selling of medical consumable	\$ 530,457	518,754	1,049,020	1,015,015

(ii) Contract balances

	June 30, 2025	December 31, 2024	June 30, 2024
Notes and accounts receivable	\$ 258,217	268,127	270,844
Less: allowance for impairment	-	-	-
Total	\$ 258,217	268,127	270,844
	June 30, 2025	December 31, 2024	June 30, 2024
Current contract liabilities	\$ 57,560	57,542	40,458

For details on notes and accounts receivable and allowance for impairment, please refer to note 6(d).

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The amount of revenue recognized for the six months ended June 30, 2025 and June 30, 2024 that was included in the contract liability balance at the beginning of the period were \$55,922 thousand \$32,488 thousand, respectively.

The major change in the balance of contract assets and liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received.

(o) Remuneration to employees and directors

On June 19, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Articles, if the Company has profit in a given fiscal year, more than 5% of the profits shall be allocated as employees' remuneration and salaries adjustment to those base-level employees and no more than 1.6% of the profits shall be allocated as directors' remuneration. Prior to the amendments, the Article of Incorporation stipulated that, if the Company has profit in a given fiscal year, no less than 5% shall be allocated as employee's remuneration and no more than 1.6% shall be allocated as directors' remuneration. However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss.

The Company's estimated remuneration is as follows:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Employees' remuneration	\$ 7,096	8,281	16,098	16,693
Directors' remuneration	2,243	2,650	5,151	5,342
	\$ 9,339	10,931	21,249	22,035

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Association. The above remuneration were included in the operating expenses of the six months ended June 30, 2025 and June 30, 2024. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

The remunerations to employees amounted to \$35,687 and \$30,179, respectively, for the years ended December 31, 2024 and 2023. The remunerations to directors amounted to \$11,420 and \$9,657, respectively, for the years ended December 31, 2024 and 2023.

There was no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statement for the years of 2024 and 2023.

The related information mentioned above can be found on websites such as the Market Observation Post System.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(p) Non-operating income and expenses

(i) Interest income

	<u>For the three months ended June 30, 2025</u>	<u>For the three months ended June 30, 2024</u>	<u>For the six months ended June 30, 2025</u>	<u>For the six months ended June 30, 2024</u>
Interest income:				
Interest income from deposit	\$ 5	5	10	10
Interest income from bank deposit	4,277	3,287	8,360	6,742
Others	-	-	-	199
	<u>\$ 4,282</u>	<u>3,292</u>	<u>8,370</u>	<u>6,951</u>

(ii) Other income

	<u>For the three months ended June 30, 2025</u>	<u>For the three months ended June 30, 2024</u>	<u>For the six months ended June 30, 2025</u>	<u>For the six months ended June 30, 2024</u>
Subsidy revenue	\$ -	67	756	67
Compensation income	9	-	9	125
Rent revenue	141	500	209	500
Others	924	880	1,997	1,738
	<u>\$ 1,074</u>	<u>1,447</u>	<u>2,971</u>	<u>2,430</u>

(iii) Other gains and losses

	<u>For the three months ended June 30, 2025</u>	<u>For the three months ended June 30, 2024</u>	<u>For the six months ended June 30, 2025</u>	<u>For the six months ended June 30, 2024</u>
Foreign exchange gains (losses)	\$ (29,064)	2,218	(21,864)	14,879
Gains on financial assets at fair value through profit or loss	452	407	906	803
Gains on financial assets at amortized cost	(2,905)	1,329	(2,905)	5,149
Others	(68)	(234)	(161)	(296)
	<u>\$ (31,585)</u>	<u>3,720</u>	<u>(24,024)</u>	<u>20,535</u>

(iv) Finance costs

	<u>For the three months ended June 30, 2025</u>	<u>For the three months ended June 30, 2024</u>	<u>For the six months ended June 30, 2025</u>	<u>For the six months ended June 30, 2024</u>
Interest expense on bank borrowings	\$ 1,345	2,030	2,861	4,092
Interest expense on lease liabilities	584	458	1,024	922
	<u>\$ 1,929</u>	<u>2,488</u>	<u>3,885</u>	<u>5,014</u>

(q) Financial instruments

Except for the content mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information please refer to note 6(q) of the consolidated financial statements for the year ended December 31, 2024. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(g) of the consolidated financial statements for the year ended December 31, 2024.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

As of June 30, 2025, December 31, 2024 and June 30, 2024, 41%, 23% and 29% of the Group's notes and accounts receivable were concentrated on three, one and two specific customers respectively. Accordingly, concentrations of credit risk exist.

2) Receivables securities

For credit risk exposure of notes and trade receivables, please refer to note 6(d).

Other financial assets at amortized costs Mainly time deposits. These financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. The correlation credit risk , please refer to note 6(d).

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	Carrying amount	Contractual cash flows	1 year	1-2 years	2-5 years	Over 5 years
June 30, 2025						
Non-derivative financial liabilities						
Notes payable	\$ 102	102	102	-	-	-
Accounts payable	90,144	90,144	90,144	-	-	-
Other payables	146,189	146,189	146,189	-	-	-
Payables on machinery and equipment	3,906	3,906	3,906	-	-	-
Dividends payable	346,492	346,492	346,492	-	-	-
Long-term borrowings (including current portion)	371,330	374,543	152,827	135,335	86,381	-
Lease liabilities (current and non-current)	307,370	340,199	16,867	17,745	31,732	273,855
	\$ 1,265,533	1,301,575	756,527	153,080	118,113	273,855
December 31, 2024						
Non-derivative financial liabilities						
Notes payable	\$ 289	289	289	-	-	-
Accounts payable	114,547	114,547	114,547	-	-	-
Other payables	140,334	140,334	140,334	-	-	-
Payables on machinery and equipment	7,995	7,995	7,995	-	-	-
Long-term borrowings (including current portion)	446,229	450,729	152,103	144,692	153,934	-
Lease liabilities (current and non-current)	294,404	326,320	10,692	9,283	27,849	278,496
	\$ 1,003,798	1,040,214	425,960	153,975	181,783	278,496

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	Carrying amount	Contractual cash flows	1 year	1-2 years	2-5 years	Over 5 years
June 30, 2024						
Non-derivative financial liabilities						
Notes payable	\$ 163	163	163	-	-	-
Accounts payable	135,034	135,034	135,034	-	-	-
Other payables	149,787	149,787	149,787	-	-	-
Payables on machinery and equipment	85,936	85,936	85,936	-	-	-
Dividends payable	311,843	311,843	311,843	-	-	-
Long-term borrowings (including current portion)	530,137	536,221	161,673	152,832	221,716	-
Lease liabilities (current and non-current)	300,757	333,572	13,302	9,284	27,849	283,137
	\$ 1,513,657	1,552,556	857,738	162,116	249,565	283,137

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

(iii) Market risk

1) Currency risk

The Group's significant exposure to foreign currency risk was as follows:

	June 30, 2025			December 31, 2024			June 30, 2024		
	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD	Foreign currency (in thousands)	Exchange rate	NTD
Financial assets									
Monetary items									
USD	\$ 8,249	29.85	246,237	11,288	32.78	370,032	11,212	32.43	363,606
EUR	833	35.06	29,204	781	34.15	26,670	674	34.70	23,388
JPY	82,925	0.21	17,211	31,051	0.21	6,528	84,410	0.20	17,030
PHP	199,927	0.53	105,613	193,523	0.57	109,714	159,101	0.55	87,941
CNY	11,437	4.17	47,728	16,501	4.48	73,858	13,235	4.45	58,829
Investments accounted for using equity method									
USD	15,964	29.85	476,513	15,561	32.78	510,102	15,165	32.43	491,789
PHP	156,992	0.53	82,932	131,558	0.57	74,584	105,546	0.55	58,339
Financial liabilities									
Monetary items									
USD	2,173	29.85	64,864	2,662	32.78	87,245	2,295	32.43	74,441
EUR	130	35.06	4,567	262	34.15	8,933	178	34.70	6,183
JPY	12,708	0.21	2,638	42,356	0.21	8,905	43,624	0.20	8,801
PHP	11,863	0.53	6,266	13,200	0.57	7,484	11,768	0.55	6,505

The Group's exposure to foreign currency risk arise from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, accounts receivables, other receivables, accounts payable, other payables and payables on machinery and equipment that are denominated in foreign currency.

A depreciation (appreciation) of 1% of the NTD against the foreign currency for the six months ended June 30, 2025 and June 30, 2024, would have increased (decreased), the net profit before tax by \$3,677 thousand \$4,549 thousand, respectively. The analysis is performed on the same basis for 2024.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

Since the Group has many kinds of functional currencies, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For the six months ended June 30, 2025 and June 30, 2024, foreign exchange gains or losses (including realized and unrealized portions) amounted to \$(21,864) thousand \$14,879 thousand, respectively.

2) Interest rate analysis

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1% basic points, the Group's net profit before tax would have decreased / increased by \$1,857 thousand \$2,651 thousand for the six months ended June 30, 2025 and June 30, 2024, respectively, with all other variable factors remain constant. This is mainly due to the Group's borrowing at floating rates.

3) Other market price risk

For the six months ended June 30, 2025 and June 30, 2024, the sensitivity analyzes for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss as illustrated below:

Prices of securities at the reporting date	For the six months ended June 30			
	2025		2024	
	Other comprehensive income before tax	Net profit before tax	Other comprehensive income before tax	Net profit before tax
Increasing 1%	\$ -	<u>1,212</u>	-	<u>1,194</u>
Decreasing 1%	\$ -	<u>(1,212)</u>	-	<u>(1,194)</u>

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Fair value of financial instruments

1) Fair value hierarchy

The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows, however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	June 30, 2025				
	Fair value				
	<u>Book value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 121,186	121,186	-	-	121,186
Financial assets measured at amortized cost					
Cash and cash equivalents	1,244,353	-	-	-	-
Financial assets measured at amortized cost	441,044	-	-	-	-
Receivables	258,217	-	-	-	-
Other financial assets	4,718	-	-	-	-
Subtotal	1,948,332	-	-	-	-
Total	<u>\$ 2,069,518</u>	<u>121,186</u>	<u>-</u>	<u>-</u>	<u>121,186</u>
Financial liabilities measured at amortized cost					
Notes and accounts payable	\$ 90,246	-	-	-	-
Other payables	146,189	-	-	-	-
Payables on machinery and equipment	3,906	-	-	-	-
Dividends payable	346,492	-	-	-	-
Long-term borrowings (including current portion)	371,330	-	-	-	-
Lease liabilities (current and non-current)	307,370	-	-	-	-
Total	<u>\$ 1,265,533</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	December 31, 2024				
	Fair value				
	<u>Book value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 120,280	120,280	-	-	120,280
Financial assets measured at amortized cost					
Cash and cash equivalents	1,236,955	-	-	-	-
Financial assets measured at amortized cost	239,213	-	-	-	-
Receivables	268,127	-	-	-	-
Other financial assets	4,256	-	-	-	-
Subtotal	1,748,551	-	-	-	-
Total	<u>\$ 1,868,831</u>	<u>120,280</u>	<u>-</u>	<u>-</u>	<u>120,280</u>
Financial liabilities measured at amortized cost					
Notes and accounts payable	\$ 114,836	-	-	-	-
Other payables	140,334	-	-	-	-
Payables on machinery and equipment	7,995	-	-	-	-
Long-term borrowings (including current portion)	446,229	-	-	-	-
Lease liabilities (current and non-current)	294,404	-	-	-	-
Total	<u>\$ 1,003,798</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	June 30, 2024				
	Fair value				
	<u>Book value</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 119,394	119,394	-	-	119,394
Financial assets measured at amortized cost					
Cash and cash equivalents	1,537,662	-	-	-	-
Financial assets measured at amortized cost	102,817	-	-	-	-
Receivables	270,844	-	-	-	-
Other financial assets	4,224	-	-	-	-
Subtotal	1,915,547	-	-	-	-
Total	<u>\$ 2,034,941</u>	<u>119,394</u>	<u>-</u>	<u>-</u>	<u>119,394</u>
Financial liabilities measured at amortized cost					
Notes and accounts payable	\$ 135,197	-	-	-	-
Other payables	149,787	-	-	-	-
Payables on machinery and equipment	85,936	-	-	-	-
Dividends payable	311,843	-	-	-	-
Long-term borrowings (including current portion)	530,137	-	-	-	-
Lease liabilities (current and non-current)	300,757	-	-	-	-
Total	<u>\$ 1,513,657</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

2) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

When the financial instruments of the Group are traded in an active market, its fair value is illustrated by the category and nature as follows:

The fair value of listed stocks and funds traded in an active market is based on the market quoted price.

Measurements of fair value of financial instruments without an active market are based on valuation technique or quoted price from a competitor. Fair value, measured by using valuation technique that can be extrapolated from either similar financial instruments or discounted cash flow method or other valuation techniques, including models, is calculated based on available market date at the reporting date.

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

3) Categories and fair values of financial instruments

The Group strives to use market observable inputs when measuring assets and liabilities. Different levels of the fair value hierarchy to be used in determining the fair value of financial instruments are as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

For the six months ended June 30, 2025 and June 30, 2024, there were no change on the fair value hierarchy of financial asset.

(r) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(r) of the consolidated financial statements for the year ended December 31, 2024.

(s) Capital management

Management believes that the objectives, policies and processes of capital management of the Group has been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2024. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2024. Please refer to Note 6(s) of the consolidated financial statements for the year ended December 31, 2024 for further details.

(t) Investing and financing activities not affecting current cash flow

The Group's financial activities which did not affect the current cash flow for the six months ended June 30, 2025 and June 30, 2024 were as follows:

- (i) For right-of-use assets under leases, please refer to note 6(g).
- (ii) Reconciliation of liabilities arising from financial activities was as follows:

	January 1, 2025	Cash flows	Non-cash changes		
			Foreign exchange movement	Other	June 30, 2025
Long-term borrowings (including current portion)	\$ 446,229	(74,899)	-	-	371,330
Lease liabilities (current and non-current)	294,404	(6,928)	-	19,894	307,370
Total liabilities from financial activities	\$ 740,633	(81,827)	-	19,894	678,700

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	January 1, 2024	Cash flows	Non-cash changes			June 30, 2024
			Foreign exchange movement	Other	June 30, 2024	
Long-term borrowings (including current portion)	\$ 593,693	(64,485)	929	-	530,137	
Lease liabilities (current and non-current)	300,837	(6,419)	2	6,337	300,757	
Total liabilities from financial activities	<u>\$ 894,530</u>	<u>(70,904)</u>	<u>931</u>	<u>6,337</u>	<u>830,894</u>	

(7) Related-party transactions:

(a) Names and relationship with the Group

Name	Relationship with the Group
Keyao Co., Ltd.	The entity has significant influence over the Group
Yide Co., Ltd.	Other related party
Yisheng Co., Ltd.	Other related party

(b) Significant transactions with related parties:

Payables to related parties

Payables to related parties of the Group were as follows :

Account	Class of related parties	June 30, 2025	December 31, 2024	June 30, 2024
Dividends payable	Significant Influencers-Keyao Co., Ltd.	\$ 34,980	-	30,546
Dividends payable	Others	24,215	-	21,794
		<u>\$ 59,195</u>	<u>-</u>	<u>52,340</u>

(c) Key management personnel compensation

Key management personnel compensation was comprised as below:

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the six months ended June 30, 2025	For the six months ended June 30, 2024
Short-term employee benefits	\$ 6,562	6,710	13,609	13,345
Post-employment benefits	178	174	357	348
	<u>\$ 6,740</u>	<u>6,884</u>	<u>13,966</u>	<u>13,693</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(8) Assets Pledged as security:

Pledged assets	Pledged to secure	June 30, 2025	December 31, 2024	June 30, 2024
Other current financial assets:				
Restricted bank deposit	Purchase guarantee	\$ 601	601	601
Property, plant and equipment:				
Land	Credit of short-term borrowings	- -	- -	91,834
Buildings and structures	Credit of short-term borrowings	- -	- -	153,047
		\$ 601	601	245,482

(9) Commitments and contingencies:

(a) Contingencies

In prior years, the Group entered into the license agreement which has expired with a supplier. On July 5, 2018, the supplier filed a complaint which has not completed accusing the Group. The Group assess there is no significant impact on its financial statements.

(b) Notes issued as guarantee

	June 30, 2025	December 31, 2024	June 30, 2024
Bank borrowings and lease guarantee	\$ 1,913,883	1,913,340	2,068,365

(c) The agreements for expansion of the factory and purchases of machinery and equipment

	June 30, 2025	December 31, 2024	June 30, 2024
Total contract price	\$ 22,315	33,707	30,561
Paid amount	\$ 11,918	24,855	20,535

(10) Losses Due to Major Disasters: None

(11) Subsequent Events: None

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(12) Other:

A summary of employee benefits, depreciation, and amortization, by function, is as follows:

By item	By function			For the three months ended June 30, 2025			For the three months ended June 30, 2024		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total			
Employee benefits									
Salary	60,176	27,071	87,247	54,960	27,115	82,075			
Labor and health insurance	4,799	1,704	6,503	4,390	2,007	6,397			
Pension	1,580	1,022	2,602	1,586	981	2,567			
Remuneration of directors	-	2,243	2,243	-	2,650	2,650			
Others	2,994	1,243	4,237	2,984	1,398	4,382			
Depreciation	38,024	3,853	41,877	36,252	2,802	39,054			
Amortization	590	557	1,147	365	528	893			

By item	By function			For the six months ended June 30, 2025			For the six months ended June 30, 2024		
	Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total			
Employee benefits									
Salary	119,647	56,379	176,026	108,577	54,311	162,888			
Labor and health insurance	9,711	4,071	13,782	8,590	3,903	12,493			
Pension	3,191	2,052	5,243	3,124	1,974	5,098			
Remuneration of directors	-	5,151	5,151	-	5,342	5,342			
Others	6,060	2,478	8,538	5,893	2,573	8,466			
Depreciation	76,083	6,994	83,077	71,559	5,519	77,078			
Amortization	1,075	1,050	2,125	722	1,062	1,784			

(d) Seasonality of operations

The Group's operations were not affected by seasonality or cyclical factors.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(13) Other disclosures:

(a) Information on significant transactions:

The followings is the information on the Group's significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the six months ended June 30, 2025:

(i) Loans to other parties: None.

(ii) Guarantees and endorsements for other parties:

(In thousands of NTD and USD)

Number	Name of guarantor	Counterparty of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise (Note 2)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 1)	Parent company endorsements/guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/guarantees to third parties on behalf of parent company	Endorsements/guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company (Note 3)										
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	2	207,894	99,540 (USD 3,000)	89,550 (USD 3,000)	-	-	2.72 %	339,561	Y	N	N

Note 1: The total amount for the guarantees and endorsements provided by the Company to external entities shall not exceed 49% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to external entities shall not exceed 49% of the Company's net worth.

Note 2: The total amount for the guarantees and endorsements provided by the Company to any individual entity shall not exceed 30% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to any individual entity shall not exceed 30% of the Company's net worth.

Note 3: Relationship with the Company

1. Ordinary business relationship.
2. An entity, directly and indirectly, owned more than 50% voting shares of a guarantor.
3. A guarantor, directly and indirectly, owned more than 50% voting shares of an entity.
4. An entity, directly and indirectly, owned more than 90% voting shares of a guarantor.
5. Fulfillment of contractual obligations by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
6. An entity that is guaranteed and endorsed by all capital contributing shareholders in proportion to their shareholding percentages.
7. Peer engaged in the escrow of the sales contract on pre-sale house under the Consumer Protection Act.

(iii) Information regarding securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(In thousands of NTD and shares)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Remark
				Shares/Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	Capital Money Market Fund	None	Current financial assets at fair value through profit or loss	641	10,861	- %	10,861	
"	Yuanta Wan Tai Money Market Fund	"	"	2,497	39,676	- %	39,676	
"	Franklin Templeton Sinoam Money Market Fund	"	"	2,992	32,514	- %	32,514	
"	Mega Diamond Money Market Fund	"	"	2,894	38,135	- %	38,135	
	Total				121,186			121,186

Note: If there are public markets prices, the fair value shall be evaluated by the last operating date of the accounting duration.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Information regarding related-parties purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital: None.

(v) Information regarding receivables from related-parties exceeding 100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Related party	Nature of relationship	Ending balance	Turnover rate	Overdue		Amounts received in subsequent period	Allowance for bad debts
					Amount	Action taken		
The Company	BIOTEQUE MEDICAL PHIL. INC.	Subsidiary	150,727	1.13 %	-	-	20,517	-

Note: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(vi) Significant transactions and business relationship between the parent company and its subsidiaries for the six months ended June 30, 2025:

(In thousands of New Taiwan Dollars)

No. (Note 1)	Name of company	Name of counter-party	Nature of relationship	Intercompany transactions			Percentage of the consolidated net revenue or total assets
				Account name	Amount	Trading terms	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts receivable	143,801	OA 270	3.03%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Processing costs	30,819	There is no significant difference from translation terms with non-related parties.	2.94%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other receivables	6,926	OA 270	0.15%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts payable	43,800	OA 60	0.92%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Sales revenue	32,797	There is no significant difference from translation terms with non-related parties.	3.13%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Accounts receivable	17,408	OA 120	0.37%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Other receivables	175	OA 30	-%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Other payable	27	OA 60	-%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Sales revenue	54,054	There is no significant difference from translation terms with non-related parties.	5.15%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Accounts receivable	10,863	OA 30	0.23%

Note 1: Company numbering as follows:

Parent company—0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary—1

Subsidiary to parent company—2

Subsidiary to subsidiary—3

Note 3: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Information on investees:

The following are the information on investees for the six months ended June 30, 2025 (excluding information on investees in Mainland China):

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of June 30, 2025			Net income (losses) of investee	Share of profits (losses) of investee	Remark
				June 30, 2025	December 31, 2024	Shares (in thousands)	Percentage of ownership	Carrying value			
The Company	BIOTEQUE MEDICAL PHIL. INC.	Philippines	Manufacturing and Trading of Medical equipment	299,315	299,315	4,481	100 %	476,513	18,139	18,139	Subsidiary
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Philippines	Trading of Medical equipment	6,801	6,801	670	100 %	82,932	13,859	13,859	investment through subsidiary

Note 1: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

(c) Information on investment in mainland China: None.

(14) Segment information:

There were no significant changes in the Group's segment, as well as the profit and loss measurement basis, as disclosed in the consolidated financial statements for the year ended December 31, 2024.

The Group's operating segment information and reconciliation were as follows:

	For the six months ended June 30, 2025				
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination
Revenue:					
Revenue from external customers	\$ 154,521	112,865	247,641	15,430	-
Intersegment revenue	-	7,222	-	-	(7,222)
Total revenue	<u>\$ 154,521</u>	<u>120,087</u>	<u>247,641</u>	<u>15,430</u>	<u>(7,222)</u>
Reporting segment profit or loss	<u>\$ 24,588</u>	<u>28,486</u>	<u>129,707</u>	<u>(48,530)</u>	<u>-</u>
For the three months ended June 30, 2024					
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination
Revenue:					
Revenue from external customers	\$ 166,332	89,261	257,873	5,288	-
Intersegment revenue	-	6,641	-	-	(6,641)
Total revenue	<u>\$ 166,332</u>	<u>95,902</u>	<u>257,873</u>	<u>5,288</u>	<u>(6,641)</u>
Reporting segment profit or loss	<u>\$ 23,027</u>	<u>18,540</u>	<u>150,885</u>	<u>(34,919)</u>	<u>-</u>
For the six months ended June 30, 2025					
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination
Revenue:					
Revenue from external customers	\$ 306,623	214,720	495,432	32,245	-
Intersegment revenue	-	13,262	-	-	(13,262)
Total revenue	<u>\$ 306,623</u>	<u>227,982</u>	<u>495,432</u>	<u>32,245</u>	<u>(13,262)</u>
Reporting segment profit or loss	<u>\$ 44,113</u>	<u>53,213</u>	<u>267,006</u>	<u>(59,373)</u>	<u>-</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the six months ended June 30, 2024					Total
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination	
Revenue:						
Revenue from external customers	\$ 340,982	176,639	487,954	9,440	-	1,015,015
Intersegment revenue	-	12,258	-	-	(12,258)	-
Total revenue	\$ 340,982	188,897	487,954	9,440	(12,258)	1,015,015
Reporting segment profit or loss	\$ 36,056	35,238	261,455	(15,789)	-	316,960

The material reconciling items of the above reportable segment as below:

Total reportable segment revenue should eliminate intersegment revenue by \$7,222 thousand, \$6,641 thousand, \$13,262 thousand and \$12,258 for the three months and six months ended June 30, 2025 and 2024, respectively.